DSNKY (Daiichinkyo Co) Valuation Rank


DSNKY Daiichi Sankyo Co Ltd DSNKY
73 GF Score
Price $16.45
GF Value $37.80
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Daiichinkyo Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Daiichinkyo Co Valuation Rank Related Terms

DSNKY
73GF Score
Daiichi Sankyo Co Ltd DSNKY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Daiichinkyo Co (DSNKY) Overvalued in 2026?

Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued. The current stock price of $16.45 is trading 56.5% below its estimated GF Value™ of $37.80. GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.

Key valuation signals for DSNKY:

  • Valuation Rank:
  • GF Value™: $37.80 vs. price of $16.45 (56.5% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the DSNKY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daiichinkyo Co Business Description

Address 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score

Get the complete analysis for DSNKY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.45
Price
$37.80
GF Value